Clinical Trial Update: Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) [Phase 4]

View source ↗

Summary

A Phase 4 relapse prevention study of vortioxetine (5, 10, 20 mg) in adults with major depressive disorder has completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Takeda | Conditions: Major Depressive Disorder | Phase 4 | Status: COMPLETED | Results posted: 2020-04-17